Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of ZL-82 in Healthy Adults
NCT06055023Phase 1Completed
- Sponsor
- Zenitar
- Start
- Apr 2023
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in rheumatoid arthritis (RA) and inflammatory bowel disease (IBD) comparing ZL-82 with Placebo (2 arms). Primary endpoints: Maximum Plasma Concentration at 24 hours, Time to Maximum Plasma Concentration at 24 hours and 7 more. Started Apr 2023; status: completed.
02
Drugs
ZL-82
03
Conditions
rheumatoid arthritis (RA)inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NCT06055023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06055023.